Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stop LCNP: High Dose Steroid Therapy for Late Radiation-Associated Lower Cranial Neuropathy
NCT04151082Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2019
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prednisone and methylprednisolone injection in Lower cranial neuropathy (LCN), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum tolerated dose at 3 weeks and MD Anderson Symptom Inventory - Head and Neck top 5 mean at 3 weeks. Started Oct 2019; status: recruiting.
02
Drugs
prednisonemethylprednisolone injection
03
Conditions
Lower cranial neuropathy (LCN)
Beyond the preview
Go deeper on NCT04151082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151082.